How carvedilol does not activate β
2
-adrenoceptors
Nat Commun
.
2023 Nov 30;14(1):7866.
doi: 10.1038/s41467-023-42848-5.
Authors
Robert J Lefkowitz
1
2
3
,
Howard A Rockman
4
,
Paul J Shim
5
,
Samuel Liu
5
,
Seungkirl Ahn
5
,
Biswaranjan Pani
5
,
Sudarshan Rajagopal
5
6
,
Sudha K Shenoy
5
,
Michel Bouvier
7
,
Jeffrey L Benovic
8
,
Stephen B Liggett
9
,
Robert R Ruffolo
10
,
Michael R Bristow
11
,
Milton Packer
12
13
Affiliations
1
Department of Medicine, Duke University, Durham, NC, USA. lefko001@receptor-biol.duke.edu.
2
Howard Hughes Medical Institute, Duke University, Durham, NC, USA. lefko001@receptor-biol.duke.edu.
3
Department of Biochemistry, Duke University, Durham, NC, USA. lefko001@receptor-biol.duke.edu.
4
Department of Medicine, Duke University, Durham, NC, USA. h.rockman@duke.edu.
5
Department of Medicine, Duke University, Durham, NC, USA.
6
Department of Biochemistry, Duke University, Durham, NC, USA.
7
Department of Biochemistry and Molecular Medicine, Université de Montréal, Montreal, Quebec, Canada.
8
Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA, USA.
9
Departments of Molecular Pharmacology and Medicine, University of South Florida College of Medicine, Tampa, FL, USA.
10
Research & Development, Wyeth Pharmaceuticals, Philadelphia, PA, USA.
11
Department of Medicine, Division of Cardiology, University of Colorado - Anschutz Medical Campus, Aurora, CO, USA.
12
Baylor University Medical Center, Dallas, TX, USA.
13
Imperial College, London, UK.
PMID:
38036531
PMCID:
PMC10689753
DOI:
10.1038/s41467-023-42848-5
No abstract available
Publication types
Letter
MeSH terms
Adrenergic beta-Antagonists* / pharmacology
Carvedilol / pharmacology
Receptors, Adrenergic, beta-2* / genetics
Substances
Carvedilol
Receptors, Adrenergic, beta-2
Adrenergic beta-Antagonists
Grants and funding
R01 HL056687/HL/NHLBI NIH HHS/United States
R01 HL160029/HL/NHLBI NIH HHS/United States